Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Provide National University of Singapore with Access to Bioanalytical Tech

NEW YORK (GenomeWeb) – Agilent Technologies today announced that it will provide access to its bioanalytical instruments to National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine) for use in a study of patient responses to cardiovascular medicines.

Under the terms of their arrangement, the school's department of medicine will have access to Agilent's proof-of-concept laboratory in Singapore, which includes its 6550 iFunnel quadrupole time-of-flight liquid chromatography mass spectrometry system, as well as its Capillary Electrophoresis System model 7100.

Using the technologies, NUS Medicine researchers aim to provide real-time readouts for patients to understand the risks and benefits of commonly prescribed medications throughout the lifecycle of a drug, Agilent said. The effort is beginning with heart disease therapeutics, but could later expand to other conditions such as diabetes.

"Agilent's broad range of technologies will ultimately aid in the development of new analytics for personalized patient care," NUS Medicine professor Chester Drum said in a statement. "Consideration of the patient as an individual, rather than a statistic, is where we will see the next innovations in cardiovascular medicine."

Agilent said that as part of the deal it and NUS Medicine will have opportunities to present at various industry or Agilent-led events and seminars in the Asia-Pacific region.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.